TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Viatris ( (VTRS) ) has provided an announcement.
On December 6, 2025, Viatris Inc. announced an agreement to sell its equity stake in Biocon Biologics Limited to Biocon Limited for $815 million, comprising $400 million in cash and $415 million in equity shares. This transaction, expected to close in Q1 2026, will accelerate the expiration of biosimilars non-compete restrictions, allowing Viatris to regain access to the global biosimilars market, enhancing its portfolio of generics and innovative brands.
The most recent analyst rating on (VTRS) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Viatris stock, see the VTRS Stock Forecast page.
Spark’s Take on VTRS Stock
According to Spark, TipRanks’ AI Analyst, VTRS is a Neutral.
Viatris’ overall stock score reflects a mix of positive technical momentum and strategic advancements, offset by financial performance challenges. The company’s strong earnings call and corporate events provide optimism, but profitability and valuation concerns weigh on the score.
To see Spark’s full report on VTRS stock, click here.
More about Viatris
Viatris Inc. is a global healthcare company that bridges the gap between generics and branded medications, supplying high-quality medicines to approximately 1 billion patients worldwide annually. With a diverse portfolio and a robust global supply chain, Viatris aims to address healthcare needs across various life stages and conditions.
Average Trading Volume: 9,262,322
Technical Sentiment Signal: Buy
Current Market Cap: $12.59B
For detailed information about VTRS stock, go to TipRanks’ Stock Analysis page.